Daily Briefing – August 6, 2019

“Genomind said today it will launch an enhanced version of its mental health genetic test that will feature a new, more focused report and set of services, all designed to help clinicians better understand a patient’s genetic profile and its implications for mental health treatment. Genomind Professional PGx Express, set to be launched on Saturday, is designed to furnish physicians with what the company says is the most comprehensive information available on the variants of an individual’s genetic profile known to impact mental health treatment. The format of Genomind Professional PGx Express has been restructured to provide context on genetic profiles and how they impact a patient’s journey, the company added. Using a cheek swab administered in the physician’s office, Genomind Professional PGx Express analyzes 24 genes associated with mental health, and includes access to new technology and consultative services intended to help medical providers understand the role those genetic biomarkers may play in the treatment of mental health disorders—including depression, anxiety, attention deficit hyperactivity disorder (ADHD), autism, bipolar disorder, chronic pain, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), schizophrenia, and substance abuse. Genomind said it is doubling its pharmacogenomic expert counseling resources, and will also soon add real-time chat capabilities to its clinician portal.”

““NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations, and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email qmuse@phillymag.com with pitches for NextUp. Who: Cofounders Chris Molaro and Adam Pardes launched NeuroFlow in 2016 in collaboration with the University of Pennsylvania’s neuroscience department. The founders initially aimed to develop technology that would help mental health professionals more easily diagnose Post Traumatic Stress Disorder (PTSD) in veterans. They’ve since shifted their focus toward a broader aim: enabling better access and engagement across the continuum of behavioral health care. What: NeuroFlow’s technology includes a suite of products that help therapists gather timely information from patients in between traditional office visits. Clinicians can set reminders that encourage patients to complete wellness assignments, such as journaling or guided breathing or improve patient engagement through automated motivational emails and rewards. Clinicians can load custom content into the NeuroFlow app or web-based portal to digitally administer questionnaires, removing the need for paper surveys. The software also aggregates biometric data from wearables.”